- Repligen (RGEN +17.7%) moves up on 50% higher volume in response to its announcement of preliminary revenue of $63M - 63.5M for 2014. Estimated product revenue is $60.0M - 60.5M, an increase from previous guidance of $58M - 60M and up 26 - 27% from 2013. It will report final results in March.
- Separately, the company received a $1M milestone payment from Pfizer under its license agreement for the development of compounds to potentially treat spinal muscular dystrophy.
-
2015 Guidance: Revenues: $69M - 72M; Gross Margin: >55%.